Viking Therapeutics Inc Stock
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | 0.320% | -0.795% | -22.994% | 179.319% | 228.281% | 1234.573% | - |
| Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
| Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.
1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.
2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.
News
Hot IPO Viking Is a Fjord Tough Stock
May has been an adventurous month for Viking (NYSE: VIK). The world's leading operator of river cruise sailings went public at $24 on May 1. On Wednesday, it delivered its first financial update as
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would
Where Will Viking Therapeutics Be in 5 Years?
If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the